How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update

Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about: • His dd-cfDNA “surveillance journey” and protocol development.

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protoc

How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use

In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her

Inside the ProActive Study- How Dr Sanjeev Akkina and Dr. Jessica Coleman approach the continuity of transplant recipient care

How Dr. Anand championed a surveillance protocol informed by his deep experience and research

How Dr. Batarse advocates for his patients upon early recognition of subtle rejection using cfDNA

ASBrS APP Course

Signatera MRD testing in breast cancer setting

ASBrS Symposia

Signatera MRD testing in breast cancer setting

One Year of Prospera Hearth with DQS

Advancing ADPKD Diagnosis and Management: A Case-Based Approach to Understanding the Latest Guideline & the Role of Genetic Testing

Renasight - Variants of Uncertain Significance Video

This brief video will introduce you to genetic variant classification, with a focus on variants of uncertain significance (VUSes)

Optimizing Patient Care in MIBC with MRD Testing, Real-world Clinical Cases

Low fetal fraction results for clinicians

A guide to discussing a result with low fetal fraction from Panorama NIPT with patients.

ISHLT 2025 clinical use of DQS Brent Lampert

Dr Lampert from Ohio State shares three key scenarios where DQS has added clinical value above and beyond traditional dd-cfDNA testing.

ISHLT 2025 Trifecta Heart with DQS Phil Halloran

Dr Phil Halloran walks through initial data from the Trifecta Heart study highlighting the correlation between dd-cfDNA fraction and DQS with MMDx.

ISHLT 2025 clinical use of DQS Roopa Rao

Dr Roopa Rao from IU Health shares her experience with 2 unique cases where Prospera Heart with DQS was key to their clinical care.

ISHLT 2025 DQS Background Michael Olympios

Natera's medical director, Michael Olympios, introduces the concept of donor quantity score and highlights key supportive evidence.